Portal de Periódicos da CAPES

Corticosteroids for COVID‐19 symptoms and quality of life at 1 year from admission

2021; Wiley; Volume: 94; Issue: 1 Linguagem: Inglês

10.1002/jmv.27296

1096-9071

Ignacio Pérez Catalán, Celia Roig Martí, Daniela Palomo de la Sota, Alejandro Cardenal Álvarez, María José Esteve Gimeno, Sergio Fabra Juana, Germán Herrero Rodríguez, Elena Domínguez Bajo, Núria Tornador Gaya, Jorge Usó Blasco, José Manuel Ramos,

COVID-19 Clinical Research Studies

Abstract The long‐term evolution of COVID‐19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID‐19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS‐CoV‐2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID‐19 and to administer the SF‐36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF‐36 domains for “bodily pain” and “mental health.” Corticosteroids administered in the acute phase of COVID‐19 could attenuate the presence of long‐term symptoms and improve patients’ quality of life.